Compare Mongodb Inc (MDB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Novartis AG — how do they compare? Mongodb Inc trades at $372.09 (market cap $29.24B), while Novartis AG trades at $142.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 9.2× Mongodb Inc's market cap, and Novartis AG pays a 3.31% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and Novartis AG for 82 Days on average.
| MDB | NVS | |
|---|---|---|
Market Cap | $29.24B | $268.57B |
Volume | 1,304,995 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $472.29 | $168.62 |
52-Week Low | $225.95 | $121.80 |
Typical Hold Time | 45 Days | 82 Days |
Enterprise Value | $26.86B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $363.03, up 0.64% today, with a bearish technical signal despite recent positive earnings beats. The company reported strong revenue growth, reaching $2.01 billion in 2025, but remains unprofitable with a net loss of $129.07 million. Recent news highlights AI product launches and a CEO transition, with analysts maintaining a bullish consensus price target of $456.76.
The outlook is mixed: strong revenue growth and AI initiatives offer upside, but high valuation ratios and persistent losses pose risks. Investor sentiment is cautiously optimistic, though technical indicators suggest near-term pressure. Key risks include execution challenges and competitive threats in the database market.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
